Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
AMGN:NASDAQ
Amgen Inc
$348.62
+0.78%
(+2.70) 1D
$348.00
-0.18% (-0.62)
Pre-market
Closed: Apr 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AMGN...
Open
$345.52
High
$350.69
Low
$345.50
Mkt. cap
188.15B
Avg. vol.
2.60M
Volume
474.00
Dividend
2.89%
Quarterly dividend
$2.52
Ex dividend date
May 15, 2026
P/E ratio
24.50
52-wk high
$391.29
52-wk low
$261.43
EPS
$14.23
Beta
0.47
Shares outstanding
539.69M
No. of employees
32K
News stories
From sources across the web
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
FoundedApr 8, 1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com
Next call in 6 days
Thu, Apr 30, 4:30 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (4.76 est.)USD
Revenue / Estimate
-/ (8.58B est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
8.15B
9.18B
9.56B
9.87B
Cost of goods sold
2.60B
2.67B
2.74B
2.68B
Cost of revenue
2.60B
2.67B
2.74B
2.68B
Research and development expenses
1.49B
1.74B
1.90B
2.14B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.69B
1.69B
1.72B
1.95B
Operating expense
3.20B
3.50B
3.55B
4.18B
Total operating expenses
5.81B
6.18B
6.29B
6.85B
Operating income
2.34B
3.00B
3.26B
3.01B
Other non operating income
-36.00M
-113.00M
181.00M
143.00M
EBT including unusual items
1.97B
1.57B
3.92B
1.51B
EBT excluding unusual items
1.66B
2.37B
2.72B
2.51B
Income tax expense
243.00M
136.00M
705.00M
181.00M
Effective tax rate
12.32%
8.67%
17.98%
11.96%
Other operating expenses
30.00M
68.00M
-71.00M
82.00M
Net income
1.73B
1.43B
3.22B
1.33B
Net profit margin
21.23%
15.60%
33.65%
13.51%
Earnings per share
4.90
6.02
5.64
5.29
Interest and investment income
-
-
-
408.00M
Interest expense
-723.00M
-694.00M
-685.00M
-1.06B
Net interest expenses
-723.00M
-694.00M
-685.00M
-653.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.73B
4.34B
4.57B
4.02B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer